Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RECTIV vs GONITRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
RECTIV (nitroglycerin) is a nitric oxide (NO) donor that relaxes vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate (c GMP) production, leading to vasodilation. In chronic anal fissures, it reduces internal anal sphincter pressure and improves blood flow to the anoderm.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.
FDA-approved: Treatment of moderate to severe pain associated with chronic anal fissures
Prevention of angina pectoris due to coronary artery disease,Acute relief of angina episodes,Prophylaxis for angina before exertion or stress
1 gram (0.5 mg nitroglycerin) applied intrarectally as an ointment 10-15 minutes before anticipated bowel movement, up to twice daily.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
Terminal elimination half-life is approximately 2-4 hours in healthy adults. In patients with severe hepatic impairment, half-life may be prolonged up to 8-10 hours, requiring dose adjustment.
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
Primarily hepatic metabolism via glutathione-organic nitrate reductase, with subsequent denitration and conjugation. Metabolites include inorganic nitrate and 1,2-glyceryl dinitrate. Also undergoes hydrolysis by esterases.
Extensively metabolized by mitochondrial aldehyde dehydrogenase (ALDH2) in vascular smooth muscle; also metabolized by glutathione S-transferases and cytochrome P450 (CYP3A4).
Primarily renal; approximately 60-70% of the parent drug and metabolites excreted in urine within 24 hours. Fecal elimination accounts for ~20-30% via biliary secretion. Less than 1% unchanged drug recovered in feces.
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
Approximately 60% bound to plasma proteins, primarily albumin. Binding is reversible and concentration-dependent.
60% bound, primarily to plasma albumin
Volume of distribution is approximately 2-4 L/kg, indicating extensive tissue distribution. Clinical meaning: high Vd suggests significant uptake into vascular smooth muscle and other tissues.
Approximately 3.3 L/kg; extensive tissue distribution with high affinity for vascular smooth muscle
Sublingual: approximately 40-50% due to first-pass metabolism. Oral: <10% due to extensive hepatic first-pass effect. Topical (RECTIV): systemic bioavailability is negligible (<1%) when applied as directed to the anal mucosa.
Sublingual: 40-60%; Oral (immediate-release): <10% due to first-pass hepatic metabolism; Transdermal: 70-90% (drug-in-adhesive); Intravenous: 100%
No dosage adjustment required for renal impairment. Use with caution in severe impairment due to potential for volume depletion.
No specific dose adjustment required for renal impairment. However, use with caution in severe renal dysfunction (Cr Cl <30 m L/min) due to increased risk of hypotension and methemoglobinemia.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 1 gram (0.5 mg) once daily. Child-Pugh C: contraindicated.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 50% due to decreased clearance. Child-Pugh C: Avoid use or use with extreme caution; consider alternative therapy.
Safety and efficacy not established in pediatric patients under 18 years.
Sublingual: 5-10 mcg/kg/dose, maximum 0.3 mg per dose, may repeat every 5 minutes up to 3 doses. Intravenous: Start at 0.25-0.5 mcg/kg/min, titrate up to 1-5 mcg/kg/min based on response. Not recommended for children <1 year due to limited data.
Use with caution; start at lowest effective dose (1 gram) and monitor for hypotension. Consider decreased renal/hepatic function.
Initiate at lower doses due to increased sensitivity: Sublingual: 0.15-0.3 mg; Transdermal: 0.2 mg/day patch; Intravenous: Start at 5 mcg/min, titrate slowly. Monitor for hypotension and syncope. Avoid sustained-release formulations due to prolonged half-life.
No FDA boxed warning.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension and syncope: Use with caution in patients with hypotension, hypovolemia, or those taking antihypertensives.,Severe anemia or conditions where vasodilation is detrimental.,Concomitant use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil) is contraindicated due to risk of severe hypotension.,May cause headaches and local burning or itching at application site.
Hypotension (especially with volume depletion or diuretic therapy), reflex tachycardia, tolerance (intermittent dosing with nitrate-free interval recommended), abrupt discontinuation may cause angina rebound.
Concomitant use of PDE-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil),History of hypersensitivity to nitroglycerin or any component of the formulation,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Circulatory failure (shock) or severe hypotension
Concomitant use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil), severe anemia, increased intracranial pressure, hypersensitivity to nitrates, acute myocardial infarction with low filling pressure.
No specific food restrictions. Avoid alcohol as it may worsen hypotension and headache. Grapefruit juice may increase nitroglycerin levels; avoid concurrent consumption.
Avoid alcohol consumption as it may exacerbate nitroglycerin-induced hypotension and vasodilation. No specific food interactions documented; however, patients should maintain adequate hydration. High-fat meals may delay absorption, but sublingual route minimizes this effect. Grapefruit juice has no known interaction.
Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 50 times the recommended human dose). No well-controlled studies in pregnant women; use only if clearly needed. Fetal risk cannot be ruled out.
FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: risk of fetal bradycardia, hypotension, and reduced uteroplacental perfusion; avoid near term due to risk of maternal hypotension and neonatal bradycardia.
Not recommended during breastfeeding. Drug is administered topically for hemorrhoids; systemic absorption is minimal, but no data on excretion in human milk. M/P ratio not determined.
Not recommended during breastfeeding. No data on M/P ratio; minimal excretion into breast milk expected but safety not established. Potential for infant hypotension and bradycardia.
No dose adjustment required; pharmacokinetics not studied in pregnancy. Use the same dose as in non-pregnant patients, but with caution due to lack of safety data.
No standard dose adjustment required for pregnancy; use lowest effective dose. Increased plasma volume may reduce response; titrate to effect. Avoid in severe preeclampsia or volume depletion.
RECTIV (nitroglycerin) 0.4% ointment is indicated for chronic anal fissure pain. Apply a 1-inch strip intra-anally every 12 hours for up to 8 weeks. May cause headache; monitor blood pressure. Contraindicated with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Avoid in patients with hypotension (SBP <90 mm Hg) or hypovolemia. Do not use with strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat).
GONITRO (nitroglycerin sublingual powder) is indicated for acute relief of angina pectoris. Administer one packet (0.4 mg or 0.8 mg) at onset of chest pain; may repeat every 5 minutes up to 3 doses. Ensure patient is seated or lying down to avoid hypotension. Do not confuse with oral spray; powder must be placed under tongue. Onset within 1-3 minutes. Common side effect: headache. Contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) within 24-48 hours due to severe hypotension. Monitor for orthostatic hypotension.
Apply 1-inch strip of ointment inside the anus every 12 hours using the applicator.,Wash hands before and after application.,Do not use more than 8 weeks unless directed by your doctor.,Avoid sexual activity during treatment as partner may absorb medication.,Do not take erectile dysfunction drugs (Viagra, Cialis, Levitra) while using this medication.,Seek medical help if you experience severe headache, dizziness, or fainting.,Store at room temperature away from heat and direct light.,Do not use if you have low blood pressure or are dehydrated.
Take one packet at the first sign of chest pain. Empty the entire powder under your tongue and let it dissolve. Do not swallow or rinse with water.,If pain persists after 5 minutes, take a second packet. If still no relief after 5 more minutes, take a third and call 911.,Sit or lie down when taking this medication to prevent dizziness or fainting.,Avoid alcohol; it may worsen side effects like low blood pressure.,Do not use Viagra, Cialis, Levitra, or other erectile dysfunction drugs while on this medicine—serious drop in blood pressure can occur.,Headaches are common; do not stop taking the medication. Over-the-counter pain relievers may help.,Store packets at room temperature away from moisture and heat. Do not open until ready to use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RECTIV vs GONITRO, answered by our medical review team.
RECTIV is a Nitrate Vasodilator that works by RECTIV (nitroglycerin) is a nitric oxide (NO) donor that relaxes vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate (c GMP) production, leading to vasodilation. In chronic anal fissures, it reduces internal anal sphincter pressure and improves blood flow to the anoderm.. GONITRO is a Nitrate Vasodilator that works by Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RECTIV and GONITRO depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RECTIV is: 1 gram (0.5 mg nitroglycerin) applied intrarectally as an ointment 10-15 minutes before anticipated bowel movement, up to twice daily.. The standard adult dose of GONITRO is: Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RECTIV and GONITRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RECTIV is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 50 times the recommended human dose). No well-controlled studies in. GONITRO is classified as Category C. FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.